Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1863, Issue 8, 2017, Pages 2070-2077

  Guo, Rui ^a   Nair, Sreejayan ^a  

^a UNIVERSITY OF WYOMING   (United States)

Author keywords

Biomarker; Diabetic cardiomyopathy; Heart failure; Mechanism; microRNA; Therapeutic intervention

Indexed keywords

MICRORNA;

CELL DEATH; DIABETIC CARDIOMYOPATHY; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; MITOCHONDRION; MODULATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ANIMAL; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; DIABETIC CARDIOMYOPATHIES; HUMANS; MICRORNAS;

EID: 85016510623     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2017.03.013     Document Type: Review

References (122)

1. King, H., Aubert, R.E., Herman, W.H., Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998), 1414–1431.
2. Rubler, S., Dlugash, J., Yuceoglu, Y.Z., Kumral, T., Branwood, A.W., Grishman, A., New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30 (1972), 595–602.
3. Poirier, P., Bogaty, P., Garneau, C., Marois, L., Dumesnil, J.G., Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes - importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24 (2001), 5–10.
4. Kiencke, S., Handschin, R., von Dahlen, R., Muser, J., Brunner-LaRocca, H.P., Schumann, J., Felix, B., Berneis, K., Rickenbacher, P., Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome. Eur. J. Heart Fail. 12 (2010), 951–957.
5. Bertoni, A.G., Hundley, W.G., Massing, M.W., Bonds, D.E., Burke, G.L., Goff, D.C. Jr., Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27 (2004), 699–703.
6. Bonadei, I., Gorga, E., Lombardi, C., Metra, M., Arrhythmias and cardiomyopathy: when arrhythmias come first. J. Cardiovasc. Med., 2016.
7. Schenke-Layland, K., Stock, U.A., Nsair, A., Xie, J., Angelis, E., Fonseca, C.G., Larbig, R., Mahajan, A., Shivkumar, K., Fishbein, M.C., MacLellan, W.R., Cardiomyopathy is associated with structural remodelling of heart valve extracellular matrix. Eur. Heart J. 30 (2009), 2254–2265.
8. Peters, S., Echocardiographic correlate of myocardial edema in complicated takotsubo cardiomyopathy. Int. J. Cardiol. 215 (2016), 299–300.
9. Cao, Y., Lin, S., Li, X., Acute pulmonary edema as first clinical presentation in a patient with hypertrophic cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi, 43, 2015, 828.
10. Pinto, Y.M., Elliott, P.M., Arbustini, E., Adler, Y., Anastasakis, A., Bohm, M., Duboc, D., Gimeno, J., de Groote, P., Imazio, M., Heymans, S., Klingel, K., Komajda, M., Limongelli, G., Linhart, A., Mogensen, J., Moon, J., Pieper, P.G., Seferovic, P.M., Schueler, S., Zamorano, J.L., Caforio, A.L., Charron, P., Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur. Heart J. 37 (2016), 1850–1858.
11. Codd, M.B., Sugrue, D.D., Gersh, B.J., Melton, L.J. III, Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975–1984. Circulation 80 (1989), 564–572.
12. Olbrich, H.G., Epidemiology-etiology of dilated cardiomyopathy. Z. Kardiol. 90:Suppl. 1 (2001), 2–9.
13. Rakar, S., Sinagra, G., Di Lenarda, A., Poletti, A., Bussani, R., Silvestri, F., Camerini, F., Epidemiology of dilated cardiomyopathy. A prospective post-mortem study of 5252 necropsies. The Heart Muscle Disease Study Group. Eur. Heart J. 18 (1997), 117–123.
14. Hayat, S.A., Patel, B., Khattar, R.S., Malik, R.A., Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin. Sci. 107 (2004), 539–557.
15. Boudina, S., Abel, E.D., Diabetic cardiomyopathy revisited. Circulation 115 (2007), 3213–3223.
16. Mishra, P.K., Tyagi, S.C., MicroRNomics of diabetic cardiomyopathy. Adv. Biochem. Health D 9 (2014), 179–187.
17. Fein, F.S., Diabetic cardiomyopathy. Diabetes Care 13 (1990), 1169–1179.
18. Boudina, S., Abel, E.D., Diabetic cardiomyopathy, causes and effects. Rev. Endocr. Metab. Disord. 11 (2010), 31–39.
19. Fonarow, G.C., Srikanthan, P., Diabetic cardiomyopathy. Endocrinol. Metab. Clin. N. Am. 35 (2006), 575–599 (ix).
20. Teupe, C., Rosak, C., Diabetic cardiomyopathy and diastolic heart failure — difficulties with relaxation. Diabetes Res. Clin. Pract. 97 (2012), 185–194.
21. Nichols, G.A., Gullion, C.M., Koro, C.E., Ephross, S.A., Brown, J.B., The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27 (2004), 1879–1884.
22. Nichols, G.A., Hillier, T.A., Erbey, J.R., Brown, J.B., Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 24 (2001), 1614–1619.
23. Kannel, W.B., Hjortland, M., Castelli, W.P., Role of diabetes in congestive heart failure: the Framingham study. Am. J. Cardiol. 34 (1974), 29–34.
24. Stratton, I.M., Adler, A.I., Neil, H.A., Matthews, D.R., Manley, S.E., Cull, C.A., Hadden, D., Turner, R.C., Holman, R.R., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000), 405–412.
25. Trachanas, K., Sideris, S., Aggeli, C., Poulidakis, E., Gatzoulis, K., Tousoulis, D., Kallikazaros, I., Diabetic cardiomyopathy: from pathophysiology to treatment. Hell. J. Cardiol. 55 (2014), 411–421.
26. Thrainsdottir, I.S., Aspelund, T., Thorgeirsson, G., Gudnason, V., Hardarson, T., Malmberg, K., Sigurdsson, G., Ryden, L., The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 28 (2005), 612–616.
27. Bando, Y.K., Murohara, T., Heart failure as a comorbidity of diabetes: role of dipeptidyl peptidase 4. J. Atheroscler. Thromb. 23 (2016), 147–154.
28. Seferovic, P.M., Paulus, W.J., Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur. Heart J., 36, 2015 (1718-1727, 1727a-1727c).
29. Bugger, H., Abel, E.D., Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57 (2014), 660–671.
30. Fang, Z.Y., Prins, J.B., Marwick, T.H., Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 25 (2004), 543–567.
31. Leon, L.E., Rani, S., Fernandez, M., Larico, M., Calligaris, S.D., Subclinical detection of diabetic cardiomyopathy with microRNAs: challenges and perspectives. J. Diabetes Res., 2016, 2016, 6143129.
32. Battiprolu, P.K., Gillette, T.G., Wang, Z.V., Lavandero, S., Hill, J.A., Diabetic cardiomyopathy: mechanisms and therapeutic targets. Drug Discov Today Dis. Mech. 7 (2010), e135–e143.
33. Paternostro, G., Pagano, D., Gnecchi-Ruscone, T., Bonser, R.S., Camici, P.G., Insulin resistance in patients with cardiac hypertrophy. Cardiovasc. Res. 42 (1999), 246–253.
34. Liu, Q., Wang, S., Cai, L., Diabetic cardiomyopathy and its mechanisms: role of oxidative stress and damage. J. Diabetes Investig. 5 (2014), 623–634.
35. Kajstura, J., Fiordaliso, F., Andreoli, A.M., Li, B., Chimenti, S., Medow, M.S., Limana, F., Nadal-Ginard, B., Leri, A., Anversa, P., IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 50 (2001), 1414–1424.
36. Frustaci, A., Kajstura, J., Chimenti, C., Jakoniuk, I., Leri, A., Maseri, A., Nadal-Ginard, B., Anversa, P., Myocardial cell death in human diabetes. Circ. Res. 87 (2000), 1123–1132.
37. Karakikes, I., Kim, M., Hadri, L., Sakata, S., Sun, Y., Zhang, W., Chemaly, E.R., Hajjar, R.J., Lebeche, D., Gene remodeling in type 2 diabetic cardiomyopathy and its phenotypic rescue with SERCA2a. PLoS One, 4, 2009, e6474.
38. Waddingham, M.T., Edgley, A.J., Tsuchimochi, H., Kelly, D.J., Shirai, M., Pearson, J.T., Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy. World J. Diabetes 6 (2015), 943–960.
39. Schanen, B.C., Li, X., Transcriptional regulation of mammalian miRNA genes. Genomics 97 (2011), 1–6.
40. Roma-Rodrigues, C., Raposo, L.R., Fernandes, A.R., MicroRNAs based therapy of hypertrophic cardiomyopathy: the road traveled so far. Biomed. Res. Int., 2015.
41. Wong, L.L., Wang, J., Liew, O.W., Richards, A.M., Chen, Y.T., MicroRNA and heart failure. Int. J. Mol. Sci., 17, 2016.
42. Ha, M., Kim, V.N., Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15 (2014), 509–524.
43. Condorelli, G., Latronico, M.V., Dorn, G.W. II, microRNAs in heart disease: putative novel therapeutic targets?. Eur. Heart J. 31 (2010), 649–658.
44. Condorelli, G., Latronico, M.V., Cavarretta, E., microRNAs in cardiovascular diseases: current knowledge and the road ahead. J. Am. Coll. Cardiol. 63 (2014), 2177–2187.
45. Saraiya, A.A., Li, W., Wang, C.C., Transition of a microRNA from repressing to activating translation depending on the extent of base pairing with the target. PLoS One, 8, 2013, e55672.
46. Vasudevan, S., Posttranscriptional upregulation by microRNAs. WIRES RNA 3 (2012), 311–330.
47. Valinezhad Orang, A., Safaralizadeh, R., Kazemzadeh-Bavili, M., Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation. Int. J. Genomics, 2014, 2014, 970607.
48. Blow, M.J., Grocock, R.J., van Dongen, S., Enright, A.J., Dicks, E., Futreal, P.A., Wooster, R., Stratton, M.R., RNA editing of human microRNAs. Genome Biol., 7, 2006, R27.
49. Voelter-Mahlknecht, S., Epigenetic associations in relation to cardiovascular prevention and therapeutics. Clin. Epigenetics, 8, 2016, 4.
50. Zhou, Q., Lv, D., Chen, P., Xu, T., Fu, S., Li, J., Bei, Y., MicroRNAs in diabetic cardiomyopathy and clinical perspectives. Front. Genet., 5, 2014, 185.
51. Latronico, M.V., Elia, L., Condorelli, G., Catalucci, D., Heart failure: targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment. Int. J. Biochem. Cell Biol. 40 (2008), 1643–1648.
52. Rao, P.K., Toyama, Y., Chiang, H.R., Gupta, S., Bauer, M., Medvid, R., Reinhardt, F., Liao, R., Krieger, M., Jaenisch, R., Lodish, H.F., Blelloch, R., Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ. Res. 105 (2009), 585–594.
53. Chen, J.F., Murchison, E.P., Tang, R., Callis, T.E., Tatsuguchi, M., Deng, Z., Rojas, M., Hammond, S.M., Schneider, M.D., Selzman, C.H., Meissner, G., Patterson, C., Hannon, G.J., Wang, D.Z., Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 2111–2116.
54. Melman, Y.F., Shah, R., Das, S., MicroRNAs in heart failure is the picture becoming less miRky?. Circ. Heart Fail. 7 (2014), 203–214.
55. 2 )-induced injury on cardiac myocytes via its target gene PDCD4. J. Mol. Cell. Cardiol. 47 (2009), 5–14.
56. Das, S., Ferlito, M., Kent, O.A., Fox-Talbot, K., Wang, R., Liu, D., Raghavachari, N., Yang, Y., Wheelan, S.J., Murphy, E., Steenbergen, C., Nuclear miRNA regulates the mitochondrial genome in the heart. Circ. Res. 110 (2012), 1596–1603.
57. Harada, M., Luo, X., Murohara, T., Yang, B., Dobrev, D., Nattel, S., MicroRNA regulation and cardiac calcium signaling: role in cardiac disease and therapeutic potential. Circ. Res. 114 (2014), 689–705.
58. Li, X., Du, N., Zhang, Q., Li, J., Chen, X., Liu, X., Hu, Y., Qin, W., Shen, N., Xu, C., Fang, Z., Wei, Y., Wang, R., Du, Z., Zhang, Y., Lu, Y., MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy. Cell Death Dis., 5, 2014, e1479.
59. Asrih, M., Steffens, S., Emerging role of epigenetics and miRNA in diabetic cardiomyopathy. Cardiovasc. Pathol. 22 (2013), 117–125.
60. Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., Castoldi, M., Soutschek, J., Koteliansky, V., Rosenwald, A., Basson, M.A., Licht, J.D., Pena, J.T., Rouhanifard, S.H., Muckenthaler, M.U., Tuschl, T., Martin, G.R., Bauersachs, J., Engelhardt, S., MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456 (2008), 980–984.
61. Wang, X.H., Qian, R.Z., Zhang, W., Chen, S.F., Jin, H.M., Hu, R.M., MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin. Exp. Pharmacol. Physiol. 36 (2009), 181–188.
62. Baseler, W.A., Thapa, D., Jagannathan, R., Dabkowski, E.R., Croston, T.L., Hollander, J.M., miR-141 as a regulator of the mitochondrial phosphate carrier (Slc25a3) in the type 1 diabetic heart. Am. J. Physiol. Cell Physiol. 303 (2012), C1244–C1251.
63. Zhao, F., Li, B., Wei, Y.Z., Zhou, B., Wang, H., Chen, M., Gan, X.D., Wang, Z.H., Xiong, S.X., MicroRNA-34a regulates high glucose-induced apoptosis in H9c2 cardiomyocytes. J. Huazhong Univ. Sci. Technolog. Med. Sci. 33 (2013), 834–839.
64. Panguluri, S.K., Tur, J., Chapalamadugu, K.C., Katnik, C., Cuevas, J., Tipparaju, S.M., MicroRNA-301a mediated regulation of Kv4.2 in diabetes: identification of key modulators. PLoS One, 8, 2013, e60545.
65. Kuwabara, Y., Horie, T., Baba, O., Watanabe, S., Nishiga, M., Usami, S., Izuhara, M., Nakao, T., Nishino, T., Otsu, K., Kita, T., Kimura, T., Ono, K., MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway. Circ. Res. 116 (2015), 279–288.
66. Shantikumar, S., Caporali, A., Emanueli, C., Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc. Res. 93 (2012), 583–593.
67. Lu, H., Buchan, R.J., Cook, S.A., MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc. Res. 86 (2010), 410–420.
68. Qiao, Y., Zhao, Y., Liu, Y., Ma, N., Wang, C., Zou, J., Liu, Z., Zhou, Z., Han, D., He, J., Sun, Q., Liu, Y., Xu, C., Du, Z., Huang, H., miR-483-3p regulates hyperglycaemia-induced cardiomyocyte apoptosis in transgenic mice. Biochem. Biophys. Res. Commun., 2016.
69. Li, Y., Song, Y.H., Li, F., Yang, T., Lu, Y.W., Geng, Y.J., MicroRNA-221 regulates high glucose-induced endothelial dysfunction. Biochem. Biophys. Res. Commun. 381 (2009), 81–83.
70. Zheng, D., Ma, J., Yu, Y., Li, M., Ni, R., Wang, G., Chen, R., Li, J., Fan, G.C., Lacefield, J.C., Peng, T., Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice. Diabetologia 58 (2015), 1949–1958.
71. Shen, E., Diao, X., Wang, X., Chen, R., Hu, B., MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy. Am. J. Pathol. 179 (2011), 639–650.
72. Feng, B., Chen, S., George, B., Feng, Q., Chakrabarti, S., miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab. Res. Rev. 26 (2010), 40–49.
73. Care, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M.L., Segnalini, P., Gu, Y., Dalton, N.D., Elia, L., Latronico, M.V., Hoydal, M., Autore, C., Russo, M.A., Dorn, G.W. II, Ellingsen, O., Ruiz-Lozano, P., Peterson, K.L., Croce, C.M., Peschle, C., Condorelli, G., MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 13 (2007), 613–618.
74. Duan, Y., Zhou, B., Su, H., Liu, Y., Du, C., miR-150 regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300. Exp. Cell Res. 319 (2013), 173–184.
75. van Rooij, E., Sutherland, L.B., Thatcher, J.E., DiMaio, J.M., Naseem, R.H., Marshall, W.S., Hill, J.A., Olson, E.N., Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 13027–13032.
76. Yu, M., Liu, Y., Zhang, B., Shi, Y., Cui, L., Zhao, X., Inhibiting microRNA-144 abates oxidative stress and reduces apoptosis in hearts of streptozotocin-induced diabetic mice. Cardiovasc. Pathol. 24 (2015), 375–381.
77. Costantino, S., Paneni, F., Luscher, T.F., Cosentino, F., MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart. Eur. Heart J. 37 (2016), 572–576.
78. Raut, S.K., Singh, G.B., Rastogi, B., Saikia, U.N., Mittal, A., Dogra, N., Singh, S., Prasad, R., Khullar, M., miR-30c and miR-181a synergistically modulate p53–p21 pathway in diabetes induced cardiac hypertrophy. Mol. Cell. Biochem. 417 (2016), 191–203.
79. Jeyabal, P., Thandavarayan, R.A., Joladarashi, D., Suresh Babu, S., Krishnamurthy, S., Bhimaraj, A., Youker, K.A., Kishore, R., Krishnamurthy, P., MicroRNA-9 inhibits hyperglycemia-induced pyroptosis in human ventricular cardiomyocytes by targeting ELAVL1. Biochem. Biophys. Res. Commun. 471 (2016), 423–429.
80. Torella, D., Ellison, G.M., Torella, M., Vicinanza, C., Aquila, I., Iaconetti, C., Scalise, M., Marino, F., Henning, B.J., Lewis, F.C., Gareri, C., Lascar, N., Cuda, G., Salvatore, T., Nappi, G., Indolfi, C., Torella, R., Cozzolino, D., Sasso, F.C., Carbonic anhydrase activation is associated with worsened pathological remodeling in human ischemic diabetic cardiomyopathy. J. Am. Heart Assoc., 3, 2014, e000434.
81. Dirkx, E., da Costa Martins, P.A., De Windt, L.J., Regulation of fetal gene expression in heart failure. Biochim. Biophys. Acta 1832 (2013), 2414–2424.
82. Munoz, J.P., Collao, A., Chiong, M., Maldonado, C., Adasme, T., Carrasco, L., Ocaranza, P., Bravo, R., Gonzalez, L., Diaz-Araya, G., Hidalgo, C., Lavandero, S., The transcription factor MEF2C mediates cardiomyocyte hypertrophy induced by IGF-1 signaling. Biochem. Biophys. Res. Commun. 388 (2009), 155–160.
83. Ruiz, M.A., Chakrabarti, S., MicroRNAs: the underlying mediators of pathogenetic processes in vascular complications of diabetes. Can. J. Diabetes 37 (2013), 339–344.
84. Yildirim, S.S., Akman, D., Catalucci, D., Turan, B., Relationship between downregulation of miRNAs and increase of oxidative stress in the development of diabetic cardiac dysfunction: junctin as a target protein of miR-1. Cell Biochem. Biophys. 67 (2013), 1397–1408.
85. Zhao, Y., Samal, E., Srivastava, D., Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436 (2005), 214–220.
86. Ikeda, S., He, A.B., Kong, S.W., Lu, J., Bejar, R., Bodyak, N., Lee, K.H., Ma, Q., Kang, P.M., Golub, T.R., Pu, W.T., MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol. Cell. Biol. 29 (2009), 2193–2204.
87. Moore, A., Shindikar, A., Fomison-Nurse, I., Riu, F., Munasinghe, P.E., Ram, T.P., Saxena, P., Coffey, S., Bunton, R.W., Galvin, I.F., Williams, M.J., Emanueli, C., Madeddu, P., Katare, R., Rapid onset of cardiomyopathy in STZ-induced female diabetic mice involves the downregulation of pro-survival Pim-1. Cardiovasc. Diabetol., 13, 2014, 68.
88. Liu, S., Li, W., Xu, M., Huang, H., Wang, J., Chen, X., Micro-RNA 21Targets dual specific phosphatase 8 to promote collagen synthesis in high glucose-treated primary cardiac fibroblasts. Can. J. Cardiol. 30 (2014), 1689–1699.
89. Arnold, N., Koppula, P.R., Gul, R., Luck, C., Pulakat, L., Regulation of cardiac expression of the diabetic marker microRNA miR-29. PLoS One, 9, 2014, e103284.
90. Feng, B., Cao, Y., Chen, S., Chu, X., Chu, Y., Chakrabarti, S., miR-200b mediates endothelial-to-mesenchymal transition in diabetic cardiomyopathy. Diabetes 65 (2016), 768–779.
91. Rolo, A.P., Palmeira, C.M., Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol. Appl. Pharmacol. 212 (2006), 167–178.
92. Shen, X., Zheng, S., Thongboonkerd, V., Xu, M., Pierce, W.M. Jr., Klein, J.B., Epstein, P.N., Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. Am. J. Physiol. Endocrinol. Metab. 287 (2004), E896–E905.
93. Giacco, F., Brownlee, M., Oxidative stress and diabetic complications. Circ. Res. 107 (2010), 1058–1070.
94. Magenta, A., Greco, S., Gaetano, C., Martelli, F., Oxidative stress and microRNAs in vascular diseases. Int. J. Mol. Sci. 14 (2013), 17319–17346.
95. Shan, Z.X., Lin, Q.X., Deng, C.Y., Zhu, J.N., Mai, L.P., Liu, J.L., Fu, Y.H., Liu, X.Y., Li, Y.X., Zhang, Y.Y., Lin, S.G., Yu, X.Y., miR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes. FEBS Lett. 584 (2010), 3592–3600.
96. Su, M., Wang, J., Wang, C., Wang, X., Dong, W., Qiu, W., Wang, Y., Zhao, X., Zou, Y., Song, L., Zhang, L., Hui, R., MicroRNA-221 inhibits autophagy and promotes heart failure by modulating the p27/CDK2/mTOR axis. Cell Death Differ. 22 (2015), 986–999.
97. Wang, J.X., Zhang, X.J., Li, Q., Wang, K., Wang, Y., Jiao, J.Q., Feng, C., Teng, S., Zhou, L.Y., Gong, Y., Zhou, Z.X., Liu, J., Wang, J.L., Li, P.F., MicroRNA-103/107 regulate programmed necrosis and myocardial ischemia/reperfusion injury through targeting FADD. Circ. Res. 117 (2015), 352–363.
98. Wang, K., Long, B., Li, N., Li, L., Liu, C.Y., Dong, Y.H., Gao, J.N., Zhou, L.Y., Wang, C.Q., Li, P.F., MicroRNA-2861 regulates programmed necrosis in cardiomyocyte by impairing adenine nucleotide translocase 1 expression. Free Radic. Biol. Med. 91 (2016), 58–67.
99. Wang, K., Liu, F., Zhou, L.Y., Ding, S.L., Long, B., Liu, C.Y., Sun, T., Fan, Y.Y., Sun, L., Li, P.F., miR-874 regulates myocardial necrosis by targeting caspase-8. Cell Death Dis., 4, 2013, e709.
100. Tijsen, A.J., Pinto, Y.M., Creemers, E.E., Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases. Am. J. Physiol. Heart Circ. Physiol. 303 (2012), H1085–H1095.
101. Dimmeler, S., Zeiher, A.M., Circulating microRNAs: novel biomarkers for cardiovascular diseases?. Eur. Heart J. 31 (2010), 2705–2707.
102. Zampetaki, A., Kiechl, S., Drozdov, I., Willeit, P., Mayr, U., Prokopi, M., Mayr, A., Weger, S., Oberhollenzer, F., Bonora, E., Shah, A., Willeit, J., Mayr, M., Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res. 107 (2010), 810–817.
103. Kong, L., Zhu, J., Han, W., Jiang, X., Xu, M., Zhao, Y., Dong, Q., Pang, Z., Guan, Q., Gao, L., Zhao, J., Zhao, L., Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 48 (2011), 61–69.
104. Karolina, D.S., Armugam, A., Tavintharan, S., Wong, M.T., Lim, S.C., Sum, C.F., Jeyaseelan, K., MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One, 6, 2011, e22839.
105. Wang, X., Sundquist, J., Zoller, B., Memon, A.A., Palmer, K., Sundquist, K., Bennet, L., Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2. PLoS One, 9, 2014.
106. Liu, Y., Gao, G., Yang, C., Zhou, K., Shen, B., Liang, H., Jiang, X., The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus. Int. J. Mol. Sci. 15 (2014), 10567–10577.
107. Al-Kafaji, G., Al-Mahroos, G., Al-Muhtaresh, H.A., Skrypnyk, C., Sabry, M.A., Ramadan, A.R., Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: a potential blood-based biomarker. Exp. Ther. Med. 12 (2016), 815–822.
108. Caporali, A., Meloni, M., Vollenkle, C., Bonci, D., Sala-Newby, G.B., Addis, R., Spinetti, G., Losa, S., Masson, R., Baker, A.H., Agami, R., le Sage, C., Condorelli, G., Madeddu, P., Martelli, F., Emanueli, C., Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 123 (2011), 282–291.
109. Becker, S., Florian, A., Patrascu, A., Rosch, S., Waltenberger, J., Sechtem, U., Schwab, M., Schaeffeler, E., Yilmaz, A., Identification of cardiomyopathy associated circulating miRNA biomarkers in patients with muscular dystrophy using a complementary cardiovascular magnetic resonance and plasma profiling approach. J. Cardiovasc. Magn. Reson., 18, 2016.
110. Nair, N., Kumar, S., Gongora, E., Gupta, S., Circulating miRNA as novel markers for diastolic dysfunction. Mol. Cell. Biochem. 376 (2013), 33–40.
111. Ucar, A., Gupta, S.K., Fiedler, J., Erikci, E., Kardasinski, M., Batkai, S., Dangwal, S., Kumarswamy, R., Bang, C., Holzmann, A., Remke, J., Caprio, M., Jentzsch, C., Engelhardt, S., Geisendorf, S., Glas, C., Hofmann, T.G., Nessling, M., Richter, K., Schiffer, M., Carrier, L., Napp, L.C., Bauersachs, J., Chowdhury, K., Thum, T., The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat. Commun., 3, 2012.
112. van Rooij, E., Olson, E.N., MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J. Clin. Invest. 117 (2007), 2369–2376.
113. Barwari, T., Joshi, A., Mayr, M., MicroRNAs in cardiovascular disease. J. Am. Coll. Cardiol. 68 (2016), 2577–2584.
114. Beg, M., Brenner, A., Sachdev, J., Borad, M., Cortes, J., Tibes, R., Kang, Y., Bader, A., Stoudemire, J., Smith, S., Kim, S., Hong, D., A phase 1 study of first-in-class microRNA-34 mimic, MRX34, in patients with hepatocellular carcinoma or advanced cancer with liver metastasis. Eur. J. Cancer, 50, 2014, 196.
115. Lee, Y., Kim, M., Han, J.J., Yeom, K.H., Lee, S., Baek, S.H., Kim, V.N., MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23 (2004), 4051–4060.
116. Montgomery, R.L., Hullinger, T.G., Semus, H.M., Dickinson, B.A., Seto, A.G., Lynch, J.M., Stack, C., Latimer, P.A., Olson, E.N., van Rooij, E., Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124 (2011), 1537–1547.
117. Chen, S., Puthanveetil, P., Feng, B., Matkovich, S.J., Dorn, G.W. II, Chakrabarti, S., Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes. J. Cell. Mol. Med. 18 (2014), 415–421.
118. Reddy, M.A., Jin, W., Villeneuve, L., Wang, M., Lanting, L., Todorov, I., Kato, M., Natarajan, R., Pro-inflammatory role of microrna-200 in vascular smooth muscle cells from diabetic mice. Arterioscler. Thromb. Vasc. Biol. 32 (2012), 721–729.
119. Zhang, H.N., Liu, J., Qu, D., Wang, L., Luo, J.Y., Lau, C.W., Liu, P.S., Gao, Z., Tipoe, G.L., Lee, H.K., Ng, C.F., Ma, R.C.W., Yao, X.Q., Huang, Y., Inhibition of miR-200c restores endothelial function in diabetic mice through suppression of COX-2. Diabetes 65 (2016), 1196–1207.
120. Callis, T.E., Pandya, K., Seok, H.Y., Tang, R.H., Tatsuguchi, M., Huang, Z.P., Chen, J.F., Deng, Z.L., Gunn, B., Shumate, J., Willis, M.S., Selzman, C.H., Wang, D.Z., MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Investig. 119 (2009), 2772–2786.
121. Nagalingam, R.S., Sundaresan, N.R., Gupta, M.P., Geenen, D.L., Solaro, R.J., Gupta, M., A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling. J. Biol. Chem. 288 (2013), 11216–11232.
122. Knezevic, I., Patel, A., Sundaresan, N.R., Gupta, M.P., Solaro, R.J., Nagalingam, R.S., Gupta, M., A novel cardiomyocyte-enriched microRNA, miR-378, targets insulin-like growth factor 1 receptor: implications in postnatal cardiac remodeling and cell survival. J. Biol. Chem. 287 (2012), 12913–12926.